(Q37971166)

26 August 2017

title

MRSA new treatments on the horizon: current status (English)

1 reference

26 August 2017

M H Wilcox

1

1 reference

26 August 2017

language of work or name

1 reference

1 December 2011

1 reference

26 August 2017

1 reference

26 August 2017

volume

42 Suppl 5

1 reference

26 August 2017

page(s)

S42-4

1 reference

Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Vancomycin concentrations in infected and noninfected human bone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

VanA-type vancomycin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Epidemiology and clinical relevance of microbial resistance determinants versus anti-Gram-positive agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Tissue penetration of telavancin after intravenous administration in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Serious infections caused by methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Early experience with linezolid for infections in orthopaedics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Efficacy and tolerability of linezolid in chronic osteomyelitis and prosthetic joint infections: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970132-2

10.1016/S0020-1383(11)70132-2

7 January 2021

Identifiers

DOI

1 reference

26 August 2017

1 reference